A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

INTRODUCTION: The sodium-glucose cotransporter 2 inhibitor dapagliflozin and the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduce bodyweight via differing and complementary mechanisms. This post hoc analysis investigated the metabolic effects and baseline associations with bodyweigh...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Diabetes Ther
Egile Nagusiak: Pereira, Maria J., Lundkvist, Per, Kamble, Prasad G., Lau, Joey, Martins, Julian G., Sjöström, C. David, Schnecke, Volker, Walentinsson, Anna, Johnsson, Eva, Eriksson, Jan W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Healthcare 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6064580/
https://ncbi.nlm.nih.gov/pubmed/29949016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0449-6
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak